Acquires Rights from UCSD to Develop Cysteamine for the Treatment of NASH Enters Convivia(TM) Formulation and Manufacturing Agreement with Patheon
NOVATO, Calif., March 19 /PRNewswire-FirstCall/ -- Raptor Pharmaceuticals Corp. ("Raptor" or the "Company") (OTC Bulletin Board: RPTP), today announced that its clinical development subsidiary, Bennu Pharmaceuticals Inc. ("Bennu"), has acquired an exclusive worldwide license to intellectual property from the University of California, San Diego ("UCSD") around the use of Cysteamine, and Delayed Release Cysteamine ("DR Cysteamine") for the treatment of Non-alcoholic Steatohepatitis ("NASH"). In collaboration with doctors from UCSD School of Medicine, Bennu plans to initiate a Phase 2a clinical study of DR Cysteamine in NASH patients in 2008.
NASH is a form of progressive liver disease resulting from triglyceride fat accumulation in vacuoles of the liver cells, which causes decreased liver function and potentially leads to cirrhosis and liver failure. Cysteamine is currently approved by the FDA for the management of nephropathic cystinosis ("cystinosis"), a genetic lysosomal storage disease characterized by the poor transport of cystine out of lysosomes.
Ted Daley, President of Bennu stated, "We are delighted to extend our relationship with UCSD. Additional rights to Cysteamine in NASH complement our license to DR Cysteamine for cystinosis and neurodegenerative diseases. In addition to our ongoing clinical trial in cystinosis, we look forward to initiating a clinical trial of DR Cysteamine in NASH patients in 2008."
In a separate announcement, Raptor said that Bennu has entered into a
formulation and manufacturing agreement for its Convivia(TM) product
candidate with Patheon Pharmaceuticals
|SOURCE Raptor Pharmaceuticals Corp.|
Copyright©2008 PR Newswire.
All rights reserved